Prostate Cancer Trial, Recruiting NCT04831983 Sponsor: University of Milano Bicocca Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT04831983
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with prostate cancer (specifically the type called adenocarcinoma), confirmed through a tissue sample test
  • People whose cancer is classified as intermediate or high risk, based on a standard medical guideline called the NCCN definition
  • People whose cancer has not spread to the lymph nodes or other parts of the body, confirmed through scans such as a bone scan, CT scan, or a specialised PET scan
  • People who are reasonably active and able to carry out daily activities (rated 0–2 on a standard health scale called the ECOG scale)
  • People who, in the treating doctor's opinion, have a life expectancy of more than 5 years
  • People whose urinary symptom score (measured by a standard questionnaire called the IPSS) is 19 or below — medication to help with urinary flow is permitted

Who may not be able to join:

  • People whose cancer has reached a more advanced local stage, specifically T3b or higher according to a standard cancer staging system (confirm with trial site)
  • People whose PSA level has been above 20 ng/ml at any point in time (PSA is a protein measured in a blood test used to monitor prostate cancer)
  • People who have previously had surgery to remove or treat the prostate, such as a radical prostatectomy or cryotherapy
  • People who have previously had radiotherapy treatment to the pelvic area
  • People who have had another type of cancer in the past, unless they have been free of that cancer for at least 5 years
  • People who have active Crohn's Disease or Ulcerative Colitis (ongoing inflammatory bowel conditions)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 039-2333663

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Milano Bicocca
Registry
ClinicalTrials.gov
Start date
15 April 2021
Est. completion
1 April 2029

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov